It has been an exciting year in oncology, with a flurry of practice-changing trials and novel treatment approaches being presented at leading conferences, including the American Society of Clinical Oncology (ASCO) and, more recently, at the World Conference on Lung Cancer (WCLC) in September.

From the emergence of ctDNA liquid biopsies to the rise of bispecific and trispecific antibodies, there’s a wealth of innovation in the pipeline. Furthermore, patients who currently have few treatment options, could soon see tangible treatment options within reach.

Ahead of the 2025 European Society of Medical Oncology (ESMO) conference, Debra Scates, Unit Director, Medical, and oncology specialist leading our i-ONE expert partnership program, provides an overview of emerging trends in the solid tumor landscape, including data to watch out for at ESMO.

Fill in the form below to download the full article.